Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tremoulet

Showing results (191-200 of 281) with videos related to

Pageof 29
Sort By:
Pediatric Blood & Cancer|November 17, 2022
Cardiovascular toxicities with pediatric tyrosine kinase inhibitor therapy: An analysis of adverse events reported to the Food and Drug AdministrationHari K Narayan, Karyn Sheline, Victor Wong, et al.
International Journal of Cardiology|August 28, 2015
Galectin-3 is a marker of myocardial and vascular fibrosis in Kawasaki disease patients with giant aneurysmsFujito Numano, Chisato Shimizu, Susan Jimenez-Fernandez, et al.
Journal of the American Heart Association|October 11, 2021
Falling Through the Cracks: The Current Gap in the Health Care Transition of Patients With Kawasaki Disease: A Scientific Statement From the American Heart AssociationNagib Dahdah, Samuel C Kung, Kevin G Friedman, et al.
The Pediatric Infectious Disease Journal|September 24, 2015
Axillary, Oral and Rectal Routes of Temperature Measurement During Treatment of Acute Kawasaki DiseaseJohn T Kanegaye, Jefferson M Jones, Jane C Burns, et al.
Cardio-Oncology (London, England)|August 13, 2020
Atlas-based measures of left ventricular shape may improve characterization of adverse remodeling in anthracycline-exposed childhood cancer survivors: a cross-sectional imaging studyHari K Narayan, Ronghui Xu, Nickolas Forsch, et al.
Human Immunology|July 6, 2010
Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistanceWen Fury, Adriana H Tremoulet, Virginia E Watson, et al.
Lancet (London, England)|February 28, 2014
Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trialAdriana H Tremoulet, Sonia Jain, Preeti Jaggi, et al.
Journal of Endocrinological Investigation|July 1, 1996
Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patientsS I Jamrozik, A P Bennet, A James-Deidier, et al.
Pediatrics International : Official Journal of the Japan Pediatric Society|May 30, 2025
A phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease and coronary artery aneurysmsKenji Furuno, Eisuke Suganuma, Hiroshi Masuda, et al.
The Lancet. Child & Adolescent Health|August 20, 2023
Subgroups of children with Kawasaki disease: a data-driven cluster analysisHao Wang, Chisato Shimizu, Emelia Bainto, et al.
Pageof 29

Showing results (191-200 of 281) with videos related to

Sort By:
Pageof 29
Pediatric Blood & Cancer|November 17, 2022
Cardiovascular toxicities with pediatric tyrosine kinase inhibitor therapy: An analysis of adverse events reported to the Food and Drug AdministrationHari K Narayan, Karyn Sheline, Victor Wong, et al.
International Journal of Cardiology|August 28, 2015
Galectin-3 is a marker of myocardial and vascular fibrosis in Kawasaki disease patients with giant aneurysmsFujito Numano, Chisato Shimizu, Susan Jimenez-Fernandez, et al.
Journal of the American Heart Association|October 11, 2021
Falling Through the Cracks: The Current Gap in the Health Care Transition of Patients With Kawasaki Disease: A Scientific Statement From the American Heart AssociationNagib Dahdah, Samuel C Kung, Kevin G Friedman, et al.
The Pediatric Infectious Disease Journal|September 24, 2015
Axillary, Oral and Rectal Routes of Temperature Measurement During Treatment of Acute Kawasaki DiseaseJohn T Kanegaye, Jefferson M Jones, Jane C Burns, et al.
Cardio-Oncology (London, England)|August 13, 2020
Atlas-based measures of left ventricular shape may improve characterization of adverse remodeling in anthracycline-exposed childhood cancer survivors: a cross-sectional imaging studyHari K Narayan, Ronghui Xu, Nickolas Forsch, et al.
Human Immunology|July 6, 2010
Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistanceWen Fury, Adriana H Tremoulet, Virginia E Watson, et al.
Lancet (London, England)|February 28, 2014
Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trialAdriana H Tremoulet, Sonia Jain, Preeti Jaggi, et al.
Journal of Endocrinological Investigation|July 1, 1996
Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patientsS I Jamrozik, A P Bennet, A James-Deidier, et al.
Pediatrics International : Official Journal of the Japan Pediatric Society|May 30, 2025
A phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease and coronary artery aneurysmsKenji Furuno, Eisuke Suganuma, Hiroshi Masuda, et al.
The Lancet. Child & Adolescent Health|August 20, 2023
Subgroups of children with Kawasaki disease: a data-driven cluster analysisHao Wang, Chisato Shimizu, Emelia Bainto, et al.
Pageof 29